You don’t cut your nose-off despite your face!!! It’s easy to remove the CEO, but an altogether different task to replace and takeover the company once the CEO has been replaced.
No plan is perfect and the armchair QB’s always have the answers after the game has been played… but, if it were up to me, the 13D effort would have been initiated through recruiting a legitimate activist who was unemotional, understood the nuances of the science, had the financial wherewithal, and the willingness to battle through the noise from both sides… I am not concerned with the noise around IncellDX, but I don’t believe that would have even been brought up had an activist been pursuing the board seat. The 13D effort was weakened significantly by the “potential” conflict of interest regardless of the legitimacy of the claim IMO… while noble, having shareholders pull resources together was also unwise IMO…
From there, the activist gains a seat on the board, inserts their influence, and affects change in a productive manner without disrupting the companies day-to-day activities… anyway I look at it, the current alternative will create a disruption IMO…
Some may argue this plan would take too long, but we’ve all probably heard the wisdom given by papa bull when he warned baby bull about rushing down to pasture… With that said, I’m in this for the long-game and have the patience to do things the right way.
The one thing I completely agree with Mr. Rosenbaum on is that Nader deserves a lot of credit for what he’s done to get leronlimab to this stage. However (IMHO), a stronger “like-minded” candidate may be needed to lead the company through its commercial evolution.
As things currently stand, I am supporting CytoDyn management’s proxy slate, but it’s a long time until October 27th…
